MARIETTA, Ga., Dec. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Mizuho Health Care Conference
Wednesday, December 11, 2024
1:1 sessions | New York, NY
Northland Growth Conference
Thursday, December 12, 2024
1:1 sessions | Virtual
Stifel MedTech West Coast Bus Tour
Thursday, December 12, 2024
1:1 sessions | Palo Alto, CA
Investors interested in meeting with senior management at these events may contact their respective Mizuho, Northland Capital or Stifel representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
| Last Trade: | US$6.62 |
| Daily Change: | 0.30 4.75 |
| Daily Volume: | 1,718,822 |
| Market Cap: | US$972.810M |
May 05, 2025 April 10, 2025 February 27, 2025 February 26, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
